This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Urologix's CEO Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Conference Call Transcript

Urologix, Inc. ( ULGX)

Lazard Capital Markets 8th Annual Healthcare Conference Call

November 16, 2011 9:00 a.m. ET

Executives

Stryker Warren, Jr. - Chief Executive Officer

Gregory Fluet - Executive Vice President & Chief Operating Officer

Analysts

Karen Koski - Lazard Capital Markets

Presentation

Karen Koski - Lazard Capital Markets

I think we will get started. My name is Karen Koski and I work in equity research at Lazard Capital Markets. We are very pleased to have Urologix here with us today. Presenting on behalf of Urologix is the company's CEO, Stryker Warren, and we invite you to ask questions at the end of the presentation. Stryker, so it’s over to you.

Stryker Warren, Jr.

Karen, thank you very much. It’s a pleasure to introduce the new Urologix to you today and much of this is driven by the recent announcement, September 6, of the exclusive worldwide license with Medtronic for the Prostiva RF therapy system. This puts Urologix into the leading position in terms of in-office solutions for benign prostate enlargement. And these two technologies are very very key to treating not only the symptomatic phase of the disease, but more importantly the longer-term implications associated with the obstructive component of the disease.

Some of the investments highlights. With the Prostiva transaction this combines the number one and number two technologies in the in-office minimally invasive space for the treatment of BPH. It has also effectively expanded our sales force, introduced additional distribution channels and what is very very important with these two technologies is that they are complementary in nature. I will share more details on that in a moment. They are both clinically proven with good reimbursement.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs